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Endothelial Gata5 transcription factor regulates
blood pressure
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Despite its high prevalence and economic burden, the aetiology of human hypertension
remains incompletely understood. Here we identify the transcription factor GATA5, as a new
regulator of blood pressure (BP). GATA5 is expressed in microvascular endothelial cells and
its genetic inactivation in mice (Gata5-null) leads to vascular endothelial dysfunction and
hypertension. Endothelial-specific inactivation of Gata5mimics the hypertensive phenotype of
the Gata5-null mice, suggestive of an important role for GATA5 in endothelial homeostasis.
Transcriptomic analysis of human microvascular endothelial cells with GATA5 knockdown
reveals that GATA5 affects several genes and pathways critical for proper endothelial func-
tion, such as PKA and nitric oxide pathways. Consistent with a role in human hypertension,
we report genetic association of variants at the GATA5 locus with hypertension traits in two
large independent cohorts. Our results unveil an unsuspected link between GATA5 and a
prominent human condition, and provide a new animal model for hypertension.
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H
ypertension is the most frequent cardiovascular risk factor
with a prevalence of 25–30% worldwide1. High blood
pressure (BP) is a well-established risk factor for
cardiovascular morbidity and mortality associated with
coronary artery disease (CAD), heart failure, stroke, as well as
progression of chronic kidney disease2. An estimated 7 million
deaths and 64 million disability-adjusted life years annually are
related to poorly controlled hypertension3. BP is a complex,
genetically determined trait, with estimates of heritability ranging
from 31 to 68% (ref. 4). In the last 2 decades, large-scale genomic
approaches have been used to identify genes/variants responsible
for BP regulation. In particular, genome-wide association studies
(GWAS) identified several loci in or near genes, many of which
were previously not suspected of controlling BP5. However,
despite significant progress, the collective effect of all BP loci
identified through GWAS explains only a small fraction (2%) of
BP heritability5. The genetic basis and pathophysiology of
hypertension remain therefore obscure.
Candidate gene approaches and genetic manipulation of animal
models have greatly contributed to the identification of the genetic
basis of several complex human traits. Among others, these
approaches have been particularly successful at uncovering genes
linked to human congenital heart disease6. This includes GATA5 in
which several mutations have been found in patients with bicuspid
aortic valves7,8 after this abnormality was reported in Gata5-null
mice9. GATA5 is a member of the GATA family of transcription
factors that regulate various aspects of cardiovascular cell
expansion and differentiation10. Within the cardiovascular
system, GATA5 is broadly but transiently expressed in
endocardial cells and in endocardial cushion cells of the atrio-
ventricular canal and outflow tract during embryogenesis11,12. In
vitro, GATA5 is necessary for differentiation of cardiogenic
precursors into endothelial/endocardial cells13.
We report that GATA5 is present in microvascular endothelial
cells and that its absence in mice leads to increased BP,
endothelial dysfunction and age-dependent end-organ damage,
which are all features of human hypertension. Mechanistically,
loss of GATA5 disrupts several pathways essential for proper
endothelial signalling and homeostasis. Consistent with a possible
role in human hypertension, we find genetic association of
variants within the GATA5 locus with prescription of anti-
hypertensive medication in two large independent cohorts. Thus,
GATA5 may be a susceptibility locus for hypertension and
possibly other endothelial-dependent human disorders.
Results
Loss of GATA5 in mice leads to hypertension. Inactivation of
Gata5 in mice leads to a partially penetrant bicuspid aortic valve9.
Full penetrance of concentric cardiac hypertrophy9 and increased
Nppa (encoding atrial natriuretic peptide) expression suggest the
existence in these mice of additional cardiovascular alterations
(Supplementary Fig. 1). Cardiac hypertrophy is often an adaptive
response to pressure overload14 and is thus a frequent condition
in patients with hypertension15. We therefore measured BP in
Gata5-null mice.
Both systolic and diastolic BP were significantly increased in
young male and female Gata5-null mice (90 days old) when
compared with their control littermates (Fig. 1a). Hydrochlor-
othiazide (HCTZ), a widely used diuretic in the treatment of
hypertension16 reduced, but did not normalize BP at either dose
used (2.7 and 8mg per day, respectively) (Fig. 1b). This effect is
similar to that observed in human hypertension17. Of note, the
expression and localization of the HCTZ target (the sodium
chloride co-transporter) was similar between Gata5-null mice and
their controls (Supplementary Fig. 2).
The renin–angiotensin–aldosterone system is the main hor-
monal regulator of BP and its activation leads to hypertension.
Expression and/or activity of several renin–angiotensin–aldoster-
one system components were measured and were either
unchanged or decreased in Gata5-null mice. The expression of
the angiotensin-converting enzyme (Ace) gene in the lung was
unchanged, whereas the hepatic expression of the Angiotensino-
gen (Agt) gene was decreased, as was the renal expression of the
Renin (Ren) gene (Fig. 1c). Plasma renin activity was also slightly
but significantly decreased in Gata5-null mice (Fig. 1d). No
changes were observed in urinary aldosterone concentrations
(Fig. 1e).
Since impaired kidney handling of salt and water balance is a
key factor in the pathophysiology of hypertension18, we analysed
GATA5 role therein. GATA5 is expressed in the kidney (Fig. 2a)
where it might affect electrolyte homeostasis. To test this
possibility, Gata5-null mice and their controls were maintained
in metabolic cages and urine and blood samples were collected.
At steady state, there were no differences in food and water intake
between the two groups. Twenty-four hour urinary excretion of
Naþ , Kþ and Cl , as well as plasma electrolyte concentrations
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Figure 1 | Gata5-null mice have low-renin hypertension. (a) Increased
systolic and diastolic BP in 90-day-old Gata5-null mice. Both genders are
hypertensive (males n¼ 14–16 per group; females n¼ 11–12 per group). The
results are reported as mean±s.e.m. *Po0.05; ***Po0.005 (two-factor
ANOVA). (b) Hypertension in Gata5-null mice is sensitive to diuretic:
hydrochlorothiazide (HCTZ) for 5 days lowered, but did not normalize BP in
Gata5-null mice at both low (þ , 2.8mg per day) and high dose (þ þ ,
8mg per day) (n¼4 per group). The results are reported as mean±s.e.m.
*Po0.05 versus Gata5þ /þ mice; ***Po0.01 versus Gata5þ /þ mice;
#Po0.05 versus untreated mice, ##Po0.01 versus untreated mice
(repeated measures two-factor ANOVA test followed by Bonferonni
correction for multiple comparisons). (c) Low-renin hypertension in Gata5-
null mice: the expression of Ace (angiotensin-converting enzyme) gene in
the lung was unchanged, while expression of Ren (renin) in the kidney and
Agt (angiotensinogen) gene in the liver was decreased. The expression of
these genes was measured by qPCR (n¼ 3–4 per group). The results are
reported as mean±s.e.m. *Po0.05 versus Gata5þ /þ mice (Mann–
Whitney test). (d) Plasma renin activity (PRA) was decreased in Gata5-null
mice versus their control littermates (n¼8–10 per group). The results are
reported as mean±s.e.m. *Po0.05 versus Gata5þ /þ mice (t-test). (e)
There are no changes in aldosterone urinary concentration as measured by
the enzyme immunoassay. (n¼ 6 per group). The results are reported as
mean±s.e.m. (t-test).
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were also unchanged. Similarly, no differences in urinary
electrolyte secretion between the Gata5-null mice and their
controls were detected in response to 24-h acute salt loading
(Supplementary Table 1). At steady state, the renal expression of
co-transporters involved in sodium reabsorption was either
unchanged or decreased in Gata5-null mice, suggesting pressure
natriuresis compensatory mechanisms (Supplementary Figs 3a,b
and 4). There were no changes in expression of components of
the anti-natriuretic intra-renal angiotensin system or of the pro-
natriuretic intra-renal dopaminergic system (Supplementary
Fig. 3c,d). Loss of GATA5 has therefore minimal effect on renal
electrolyte homeostasis.
Gata5 is predominantly expressed in renal endothelial cells. To
characterize the role of GATA5 within the kidney, we set out to
determine its expression sites. Unfortunately, none of the anti-
bodies we tested were suitable for immunohistochemistry, so we
resorted to quantitative PCR (qPCR) analysis on isolated
glomeruli and microdissected tubules (Supplementary Fig. 5).
As shown in Fig. 2b, Gata5 transcripts were enriched in the
glomerulus (60 versus nephron, Po0.05, Mann–Whitney test).
Renal Gata5 expression was reduced by 98% (Po0.001,
Mann–Whitney test) and became virtually undetectable in
kidneys and glomeruli of mice with endothelial-specific deletion
of Gata5 (eGata5-null mice) (Fig. 2c,d), indicating that Gata5
expression in the kidney is mostly endothelial. Consistent with
this, the messenger RNA (mRNA) level of key glomerular
markers such as nephrin (þ 29% versus controls, Po0.05, t-test)
and podocin (þ 31% versus controls, Po0.05, Mann–Whitney
test) was altered in Gata5-null mice (Fig. 2e) and glomerular
cellularity, was significantly increased in these mice (Fig. 2f,g).
Leucocytes infiltration was also increased twofold in renal cortex
of Gata5-null mice as assessed by CD45 immunostaining, and
they were found all around the tubules and the glomeruli
(Fig. 2h,i). Flow cytometry analysis of the renal immune
populations suggested that infiltrated CD45þ cells were macro-
phages, and that was confirmed by F4/80 kidney immunostaining
(Supplementary Fig. 6a–c). No increase in CD45þ cells
content was detected in other tissues (Supplementary Fig. 7),
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Figure 2 | Loss of Gata5 from renal endothelial cells leads to renal alterations. (a) GATA5 is expressed in the kidney as assessed by western blot
performed on total kidney extracts. (b) Gata5 is essentially expressed in the glomeruli as assessed by qPCR on isolated glomeruli (Glo) and microdissected
tubules (Tub) from Wt mice kidneys. (n¼ 3–5 per group). The results are reported as mean±s.e.m. *Po0.05 versus Gata5þ /þ mice (Mann–Whitney
test). (c,d) Specific deletion of Gata5 in endothelial cells (eGata5-null mice) virtually abolished renal and glomerular expression of Gata5 (n¼ 3 per group).
The results are reported as mean±s.e.m. *Po0.05 versus eGata5þ /þ mice (Mann–Whitney test). (e) The expression of the glomerular genes Nphs1
(nephrin) and Nphs2 (podocin) as measured by qPCR (n¼6 per group) was increased in Gata5-null mice. The results are reported as mean±s.e.m.
*Po0.05 versus Gata5þ /þ mice; ***Po0.005 versus Gata5þ /þ mice (t-test for nephrin; Mann–Whitney test for podocin). (f–i) Absence of Gata5
induces glomerular lesions (sections are stained with periodic acid Schiff; scale bar, 30mm; n¼ 5 per group) and renal inflammation as assessed by
leucocytes CD45 immunostaining (scale bar, 200mm; n¼4 per group). The results are reported as mean±s.e.m. ***Po0.005 versus Gata5þ /þ mice
(Mann–Whitney test). (j–n) Deletion of Gata5 from endothelial cells reproduces the renal phenotype of global Gata5 deletion: both Nephs1 and Nphs2
transcript levels were increased (n¼4–6 per group) as well as glomerular lesion score (scale bar, 30 mm; n¼4–6 per group) and renal leucocytes
infiltration (scale bar, 200mm; n¼4–5 per group) in eGata5-null mice in comparison with their controls. The results are reported as mean±s.e.m. *Po0.05
versus eGata5þ /þ mice; ***Po0.005 versus eGata5þ /þ mice (Mann–Whitney test).
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and the bone marrow and lymphoid organs (thymus and spleen)
immune subsets’ composition was similar between the
Gata5-null mice and their controls (Supplementary Fig. 8a,c,e).
The same renal and immune phenotype was observed in
eGata5-null mice (Fig. 2h–n; Supplementary Fig. 8b,d,f).
Together, these data suggest that lack of GATA5 from
endothelial cells promotes glomerular lesions and renal
inflammation likely reflecting altered renal endothelial cross-talk
with other cell types, which can contribute to hypertension
development19.
Endothelial Gata5 is responsible for increased BP. Presence of
Gata5 in glomerular endothelial cells raised the possibility that it
may be expressed in other endothelial vascular beds. Indeed,
GATA5 was expressed in all the human vascular endothelial
primary cell cultures tested with the highest level in peripheral
vascular cells such as dermal microvascular endothelial cells
(Fig. 3a; Supplementary Fig. 9). We therefore tested whether
GATA5 was involved in vascular function. The vasoconstrictor
response of mesenteric arteries to phenylephrine was similar in
control and Gata5-null mice (Fig. 3b). In contrast, there was
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Figure 3 | Endothelial Gata5 is responsible for increased blood pressure. (a) GATA5 is expressed in human cardiac microvascular (CM), coronary artery
(CA), dermal microvascular (DM) and pulmonary microvascular (PM) endothelial cells. (b,c) The vasoconstrictor response of Gata5-null mice mesenteric
arteries to norepinephrine is unaltered (n¼ 7 per group), while the vasodilatory response to acetylcholine is decreased (n¼ 10–11 per group). The results
are reported as mean±s.e.m. *Po0.05 versus controls (comparison of best-fit values—effector concentration for half-maximum response (EC50) and Hill
slope—using an F-test). (d–f) Deletion of Gata5 in endothelial (eGata5-null mice; n¼4–5 per group) but not smooth muscle cells (smGata5-null mice; n¼ 5
per group) decreases mesenteric arteries sensitivity to acetylcholine and increases BP (eGata5-null mice n¼ 6–10 per group; smGata5-null mice n¼ 6–9
per group). The results are reported as mean±s.e.m. *Po0.05 versus controls (two-factor ANOVA). (g) The vasodilatory response of Gata5-null mice to
diethylamine NONOate, an NO donor, is unaltered (n¼ 7 per group). The results are reported as mean±s.e.m. (comparison of best-fit values—EC50 and
Hill slope—using an F-test). (h,i) NOS3 and Akt phosphorylation are decreased in Gata5-null mice mesenteric arteries. PTEN and PDK1 phosphorylation
and expression are unaltered (n¼ 5–7 per group). Phosphorylated proteins are normalized to total proteins. Total proteins are normalized to actin. The
results are reported as mean±s.e.m. *Po0.05 versus Gata5þ /þ mice (t-test). (j) Quantification of protein nitrotyrosination in mesenteric arteries of
Gata5-null mice and their controls as measured by ELISA. 3-Nitrotyrosine content is expressed as picomole of nitrotyrosine per milligram of protein
(n¼ 5–7 per group). The results are reported as mean±s.e.m. (t-test).
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significant alteration in the vasodilatory response to acetylcholine
with a twofold increase in the effector concentration for half-
maximum response in Gata5-null mesenteric arteries, indicative
of endothelial dysfunction (Fig. 3c). To confirm the role of
endothelial GATA5 in vascular reactivity and BP regulation, we
analysed mice with specific endothelial (eGata5-null mice) or
smooth-muscle (smGata5-null mice) Gata5 deletion. The vaso-
dilatory response to acetylcholine was decreased in mesenteric
arteries from eGata5-null, but not from smGata5-null mice
(Fig. 3d,e). Similarly, BP was significantly elevated in mice lacking
Gata5 in endothelial but not in smooth muscle cells (Fig. 3f).
These results indicate that the hypertensive phenotype of Gata5-
null mice is mostly of endothelial origin.
The vasodilatory response of mesenteric arteries to ethylamine
NONOate, an NO donor was tested. Unlike what was observed
with acetylcholine, control and Gata5-null mice had a similar
response, suggesting that Gata5-null mice have altered NO
production or bioavailability not NO handling (Fig. 3g). The
activity of the endothelial nitric oxide synthase (NOS3) is
regulated by phosphorylation at multiple sites, and depends on
diverse kinases and phosphatases such as Akt and PTEN20. In the
mesenteric arteries of Gata5-null mice, the phosphorylation of
NOS3 on Threonine 495 (inhibitory) was unchanged, whereas it
was decreased by 58% on the critical activation site serine 1177,
which would lead to decreased endothelial NO production
(Fig. 3h,i; Supplementary Fig. 9). Phosphorylation of Akt was
decreased by 50% on threonine 308, suggesting that decrease in
NOS3 phosphorylation in Gata5-null mice mesenteric arteries
could rely on deregulated Akt signalling. Classically, Akt is
activated by PDK1, whereas PTEN is a major negative regulator
of the Akt pathway21. No changes in PDK1 and PTEN expression
and phosphorylation were observed, suggesting that loss of
GATA5 affects Akt activation independently of PDK1 and PTEN.
Furthermore, we also found a strong trend to increased protein
nitrotyrosination (a hallmark of oxidative stress) in Gata5-null
mice mesenteric arteries (P¼ 0.076, t-test) (Fig. 3j), reflecting a
possible imbalance in oxidative stress that may contribute to
decreased NO bioavailability22.
To further elucidate the role of GATA5 in endothelial cells, we
generated a stable GATA5 knockdown cell line (Human Dermal
Microvascular Endothelial Cell (HDMEC)-GATA5-KD) by
infecting HDMECs with a lentiviral vector containing an anti-
GATA5 short hairpin RNA (shRNA) (Fig. 4a), followed by a
transcriptomic analysis. HDMEC infected with a lentivirus
containing a control shRNA (targets no known mammalian
gene) served as control (HDMEC-pLKO-Ctrl). Transcriptomic
analysis identified 649 genes (192 increased and 457 decreased,
fold changeZ1.5 and Pr0.05, Mann–Whitney test with P value
adjusted—Benjamini and Hochberg—for multiple comparisons)
differentially regulated between HDMEC-GATA5-KD cells and
their controls (Fig. 4b; Supplementary Table 2). Functional
annotation of these genes using IPA Ingenuity showed enrich-
ment of several pathways known to play important roles in
endothelial homeostasis (Fig. 4c). The protein kinase A (PKA)
pathway, an important regulator of NOS3 activation and
endothelial function, was the most significantly enriched (P¼ 2.9
E 05, Fisher’s exact test). Quantification by qPCR of several
genes of the PKA pathway was consistent with microarray data
(PRKACB coding for the PKA catalytic subunit b, PRKAR2B
coding for the PKA regulator subunit 2b and PRKAA2 coding for
the AMPK catalytic subunit a2) (Fig. 4d). In line with the
microarray data and the in vivo findings, HDMEC-GATA5-KD
cells exhibited a significant decrease on NOS3 serine 1177
phosphorylation (Fig. 4e,f), and assessment of PKA activity by
western blot using an antibody raised against phosphorylated
serine/threonine PKA substrate motifs showed a decrease in the
phosphorylation of many PKA targets therein (Fig. 4e–g). The
mesenteric arteries of Gata5-null mice also revealed a decreased
PKA activation trend (P¼ 0.09, Mann–Whitney test) (Fig. 4h,i).
Other important pathways for endothelial homeostasis that were
disrupted included inflammatory pathways (for example, athero-
sclerosis, agranulocyte adhesion and diapedesis) represented by
the upregulation of genes such as ICAM1, BMP4 and IL6
(Fig. 4d). Altogether, these results indicate that GATA5 regulates
multiple pathways essential for endothelial homeostasis that can
directly contribute to the onset and maintenance of hypertension.
Finally, to confirm that endothelial dysfunction was inherent to
loss of GATA5, not secondary to hypertension, we treated Gata5-
null mice and their controls with hydralazine, a widely used
vascular smooth muscle cell relaxant. Hydralazine led to a
significant drop in BP in both groups (Po0.001, two-factor
analysis of variance (ANOVA) test) but did not normalize
endothelial dysfunction and reduced only partially glomerular
lesions (Fig. 5a–c). This suggests that both endothelial dysfunc-
tion and kidney glomerular injuries in Gata5-null mice are not
secondary to BP raise and are likely primary contributors to
deregulated BP. In contrast, hydralazine abrogated renal infiltra-
tion of CD45þ cells, indicating that renal inflammation is
secondary to increased BP (Fig. 5d).
Ageing and hypertension complications. Later stages of hyper-
tension are generally associated with salt sensitivity and target-
organ damage, in particular the heart and kidney18. We tested
whether the evolution of hypertension in Gata5-null mice follows
the natural history of human hypertension. A high-salt diet (8%
NaCl) increased BP in 8-month-old Gata5-null mice, while a low-
salt diet (0.025% NaCl) decreased it, without normalizing it
(Fig. 6a). Regular salt diet for 4 weeks after the end of high- or
low-salt diet treatment brought BP back to its initial level. Thus
Gata5-null mice develop salt sensitivity with age. The older
Gata5-null mice (on a regular salt diet) also developed cardiac
perivascular fibrosis (Fig. 6b) and several features of hypertensive
nephropathy with increased proteinuria and decreased
glomerular filtration rate (Fig. 6c,d). Histology revealed
segmental glomerulosclerosis with mesangial cell proliferation,
glomerular basement membrane thickening and accumulation of
extracellular matrix (Fig. 6e). Similarly, inflammatory (Et1, Ccl2,
Ccl5 and Pai1) and kidney injury (Havcr1) markers
(Supplementary Fig. 10) as well as inflammatory cell infiltration
were also increased in these older animals (Fig. 6f). The Gata5-
null mice represent, therefore, a new model of systemic
hypertension that reproduces several of the features found in
hypertensive patients.
GATA5 variants and BP-related traits in humans. To test the
clinical relevance of our findings, we asked whether genetic var-
iants at the GATA5 gene would reveal a nominal association with
hypertension (defined as prescription of anti-hypertensive med-
ication) in two large independent clinical data sets, the
ADVANCE (Action in Diabetes and Vascular Disease: Peterax
and Diamicron MR Controlled Evaluation) GWAS sub-study
(n¼ 2391) and the Ottawa Heart Genomics Study, OHGS
(n¼ 5835). The OHGS is a case–control study aimed at dis-
covering genetic variants that modify the risk of CAD indepen-
dent of diabetes (that is, diabetic patients were excluded from the
study)23, whereas ADVANCE is a factorial, randomized
controlled clinical trial assessing the effect of hypertension
treatment and glucose-lowering drugs on diabetic
complications24. Six variants within a region of 56 kb either
side of GATA5 were analysed (rs8113921, rs6061535, rs6142769,
rs6587235, rs6587239 and rs6061245). Of the six variants studied,
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two are within GATA5 and both were significantly associated
with anti-hypertensive medication in both studies when the
additive model was assumed: rs6061245 in intron 3 (ADVANCE:
P¼ 2E 03, beta¼  0.188; OHGS P¼ 0.031, beta  0.081,
frequentist association test) and rs6587239 a synonymous
polymorphism in exon 5 (ADVANCE: P¼ 6E 04,
beta¼ 0.204; OHGS P¼ 0.049, beta 0.075, frequentist
association test) (Table 1). In silico analysis of GATA5 exon 5
with Human Splicing Finder V3 (ref. 25) showed that rs6587239
was located within a region rich in splicing regulatory sites (SRSs)
and that substitution of a guanine by an adenine breaks or creates
a new SRS (Supplementary Fig. 11) and may therefore affect
GATA5 RNA splicing. Together these data suggest that GATA5
might be a susceptibility gene for human hypertension.
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Figure 4 | GATA5 regulates several pathways in endothelial cells. (a) GATA5 expression is significantly decreased in human dermal microvascular
endothelial cells infected with a lentiviral vector containing an anti-GATA5 shRNA (HDMEC-GATA5-KD). Control cells were infected with a vector
containing a control shRNA (targets no known mammalian gene) (HDMEC-pLKO-Ctrl, referred here as Ctrl). (b) Heatmap representation of the
differentially regulated genes between HDMEC-GATA5-KD cells and their controls as identified by transcriptomic analysis. Colour is function of Log2 RMA
(Affymetrix microarray, n¼ 3 per group). (c) Functional analysis of the differentially regulated genes between HDMEC-GATA5-KD cells and their controls.
Protein kinase A pathway is the most significantly enriched pathway. Fisher’s exact test P value. (d) Validation by qPCR (upper panel) of genes predicted by
microarray (lower panel) to be up- and downregulated in HDMEC-GATA5-KD endothelial cells. (n¼ 5 wells per condition). Downregulated genes: PRKACB
codes for the PKA catalytic subunit b, PRKAR2B for the PKA regulator subunit 2b and PRKAA2 for the AMPK catalytic subunit a2. Upregulated genes:
ICAM1 codes for the intercellular adhesion molecule 1, BMP4 for the bone morphogenetic protein 4 and IL6 for the interleukin 6. The results are reported as
mean±s.e.m. **Po0.01 versus Ctrl (t-test). (e) Western blot representation of phospho-NOS3, NOS3 (Ser1177) and phospho-(Ser/Thr) PKA substrate
motif in HDMEC-GATA5-KD cells and their controls. (f) Phosphorylation of NOS3 on Ser1177 is decreased in HDMEC-GATA5-KD cells (performed twice,
2–3 wells per condition). Phospho-NOS3 is normalized to total NOS3. NOS3 is normalized to actin. The results are reported as mean±s.e.m. *Po0.05
versus Ctrl (Mann–Whitney test). (g) Phosphorylation of (Ser/Thr) PKA substrate motif is decreased in HDMEC-GATA5-KD cells (performed twice, 2–3
wells per condition). Phospho-(Ser/Thr) PKA substrate motif (between 25 and 250 kDa) is normalized to actin. The results are reported as mean±s.e.m.
*Po0.05 versus Ctrl (Mann–Whitney test). (h) Western blot representation of phospho-(Ser/Thr) PKA substrate motif in mesenteric arteries of Gata5-
null mice and their controls. (i) In mesenteric arteries of Gata5-null mice, there is a trend to decrease in the (Ser/Thr) PKA substrate motif phosphorylation
(n¼4–5 per group). Phospho-(Ser/Thr) PKA substrate motif (between 25 and 250 kDa) is normalized to actin. The results are reported as mean±s.e.m.
(Mann–Whitney test).
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Discussion
The data presented identify GATA5 as a new regulator of BP. In
mice, loss of GATA5 leads to a hypertensive phenotype that
reproduces several of the features of human hypertension,
including vascular dysfunction, salt sensitivity and target-organ
damage. Association between GATA5 sequence variants and use
of hypertension medication in two large independent studies
suggest that GATA5 might be relevant to human hypertension.
Our results demonstrate that GATA5 is expressed in adult
microvascular endothelial cells, where it regulates numerous
genes and pathways required for endothelial homeostasis and BP
regulation. Clinical studies suggest that endothelial dysfunction
plays a precursor role in the hypertensive pathophysiology.
Endothelium-dependent vasodilation is impaired in the offspring
of patients with hypertension26 and it has been shown that
individuals with a positive family history of hypertension have an
abnormal L-arginine uptake27. Impairment of endothelial
function in patients with pre-hypertension28 further suggests
that endothelial dysfunction may promote the development of
hypertension. Animal models of hypertension also strongly
support that concept. Experimental inhibition of NO, either
pharmacologically by administration of L-NAME29 or genetically
by inactivation of NOS3 (ref. 30) increases BP. In contrast,
pharmacological enhancement of NOS activity restores
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Figure 5 | Effects of BP normalization on Gata5-null mice renal and vascular alterations. (a) Administration of hydralazine (a smooth muscle cell
relaxant) for 4 weeks decreased blood pressure similarly in both Gata5-null mice and their controls (n¼ 5–7 per group). The results are reported as
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Gata5-null mice (sections are stained with periodic acid Schiff; scale bar, 30 mm; n¼ 5–7 per group). *Po0.05 versus controls; #Po0.05 versus
corresponding untreated mice (two-factor ANOVA followed by Bonferonni correction for multiple comparisons). (d) Hydralazine decreased completely
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corresponding untreated mice (two-factor ANOVA followed by Bonferonni correction for multiple comparisons).
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endothelial function and decreases BP in spontaneously
hypertensive rats31. In this respect, our finding that loss of
GATA5 decreases vascular NO bioavailability is noteworthy.
Transcriptomic analysis of endothelial cells suggest that this could
be directly related to the decreased expression and activity of
kinases such as PKA (PKA-cat b and PRKAR2) and AMPK
(AMPKa2) that phosphorylate and activate NOS3 and its direct
upstream activator Akt32. In endothelial cells, PKA directly
phosphorylates NOS3 and induces production of nitric oxide in
response to shear stress33, whereas b-adrenergic stimulation of
NOS3 phosphorylation in bovine endothelial cells depends on
PKA activation of Akt34. Similarly, AMPK activates NOS3 in
response to various stimuli, and genetic inactivation of AMPKa2
attenuates atorvastatin-induced NOS3 phosphorylation in vivo35.
In addition to their direct effect on NOS3, these kinases are
central regulators of the stress response either through their
effects on vascular wall integrity or on the production/buffering
of reactive oxygen species (ROS). Thus, AMPKa2, which is
significantly decreased in the absence of GATA5, is central to
endothelial stress response including regulation of NADPH
oxidase36,37. In fact, AMPKa2 acts as a physiological suppressor
of ROS production and has also been shown to have
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diet (HSD, 8% NaCl) for 6 weeks or low-salt diet (LSD, 0.02% NaCl) for 10 days. HSD increased BP in Gata5-null mice, while LSD decreased it. A regular
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correction for multiple comparisons). (b) Increased perivascular fibrotic area to vessel diameter ratio (PFA/VD) in old Gata5-null mice. Sections are stained
with Masson’s Trichrome (scale bar, 100mm; n¼ 5–7 per group). The results are reported as mean±s.e.m. *Po0.05 versus Gata5þ /þ mice (t-test).
(c,d) Kidney dysfunction in 12-months-old Gata5-null mice is characterized by decreased glomerular filtration rate (GFR) and increased urinary protein
excretion (n¼ 5–6 per group). The results are reported as mean±s.e.m. *Po0.05 versus Gata5þ /þ mice (t-test). (e) Periodic acid Schiff (PAS) staining
showing significant alterations of glomerular structure in old Gata5-null mice (scale bar, 30mm; n¼ 5–7 per group). Quantification is on the right. The
results are reported as mean±s.e.m. ***Po0.005 versus Gata5þ /þ mice (t-test). (f) Significant increase in inflammatory cells infiltration in Gata5-null
mice kidneys as assessed by CD45 (leucocytes) immunostaining (scale bar, 200 mm; n¼ 5–7 per group). The results are reported as mean±s.e.m.
***Po0.005 versus Gata5þ /þ mice (t-test).
Table 1 | Logistic regression analysis results for HTN in the OHGS (n¼ 5,835) and ADVANCE (n¼ 2,301) studies.
SNP MA MAF Additive model
All HTN Non-HTN Beta s.e. P
OHGS
rs6587239 T 0.487 0.497 0.479 0.0725 0.0368 0.0492
rs6061245 T 0.499 0.488 0.508 0.0809 0.0374 0.0307
ADVANCE
rs6587239 T 0.484 0.510 0.460 0.2037 0.0595 0.0006
rs6061245 T 0.496 0.473 0.517 0.1879 0.0610 0.0020
ADVANCE, Action in Diabetes and Vascular Disease: Peterax and Diamicron MR Controlled Evaluation; HTN, patients with anti-hypertensive medication; MA, minor allele; MAF, minor allele frequency;
Non-HTN, patients without anti-hypertensive medication; OHGS, Ottawa Heart Genomics Study; SNP, single-nucleotide polymorphism.
Crude betas are given for the minor allele. Results are corrected for coronary artery disease status in the OHGS study. MAFs are given for all tested individuals, those who have been prescribed anti-
hypertensive medication (HTN) and those without prescription of anti-hypertensive medication (non-HTN). Results are calculated assuming an additive model.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9835
8 NATURE COMMUNICATIONS | 6:8835 |DOI: 10.1038/ncomms9835 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
anti-inflammatory effects on endothelial cells38. Similarly, PKA
inhibits transcription of BMP4, which stimulates ROS production
in endothelial cells and has been shown to have hypertensive and
pro-inflammatory effects on the vasculature39,40. Of note, our
ex vivo observations show that PKA activity is decreased, whereas
BMP4 expression is upregulated in endothelial cells with GATA5
knockdown. In addition to alteration of several endothelial-
signalling pathways, loss of GATA5 upregulated the expression of
pro-inflammatory molecules (ICAM1, IL6) that would also be
expected to contribute to endothelial dysfunction and to
participate in maintaining the hypertensive phenotype and the
inflammatory process that accompanies organ damage.
Noteworthy, the Tie2 promoter used to delete Gata5 from
endothelial cells is also active in the myeloid lineage41. However,
our experimental observations suggest that GATA5 has no direct
major effect on the immune system, and that macrophage
infiltration in Gata5-null mice was secondary to increased BP and
specific to the kidney, not the reflection of a systemic immune
disorder. In fact, results from the Immunological Genome Project
suggest that GATA5 is not expressed at an appreciable level in
any immune population or stage of development42. Therefore, the
phenotype of eGata5-null mice most likely results from
endothelial deletion of Gata5 from endothelial cells and reflects
GATA5 function in endothelial cells but not in other cells of the
haematopoietic lineage.
Control of BP requires complex integration of regulatory
mechanisms across multiple physiological systems (renal, cardi-
ovascular, sympathetic and endocrine)18. By its effects on
endothelial homeostasis, GATA5 may also affect BP through
mechanisms that go beyond the vascular system. Pressure
natriuresis is a key mechanism for long-term sodium and water
balance control. Increasing BP is a mean of achieving these
balances in the face of intra-renal disturbances such as reduction
in glomerular filtration rate or increase in tubular reabsorption43.
It is therefore possible that endothelial dysfunction also affects
Gata5-null mice renal arteries and blood flow, leading to
decreased renal perfusion as observed in pharmacological and
genetic models of NOS inhibition44. This could shift the pressure
natriuresis to higher BP, and the autoregulatory mechanisms in a
way that require a higher renal perfusion pressure to maintain
renal blood flow and filtration to sustain normal excretion of
sodium43. Furthermore, although GATA5 does not appear to
regulate BP through a direct effect on renal sodium handling and
excretion, its loss leads to kidney alterations that in turn may
contribute to BP increase. Glomerular injuries are usually
considered as consequences of increased BP rather than active
initiators of the pathogenesis of hypertension45. A recent study,
however, demonstrated that local glomerular increase in oxidative
stress through podocyte-specific overexpression of NOX5
increases BP46. The mechanisms by which loss of GATA5 lead
to glomerular injuries are not clear, but could involve endothelial
cell-mediated podocyte alterations, a key feature in the
progression of glomerular lesions47,48, or secretion of molecules
such as BMP4, which is known to promote glomerular injuries49.
Alteration in the pre-glomerular autoregulatory mechanisms may
also contribute to the progression of glomerular injuries in Gata5-
null mice, since attenuation of these lesions by hydralazine
suggests the participation of increased BP in glomerular lesion
progression. Renal inflammation, even if secondary, is also a
factor that likely sustains BP increase in Gata5-null mice50. The
exact function and mechanisms of action of GATA5 in the kidney
warrant further investigations. Be it as it may, our data clearly
show that loss of GATA5 from endothelial cells interferes with
multiple systems involved in BP regulation.
Low-renin hypertension is a form of hypertension that
is particularly frequent in the Afro-American population
(up to 52%)51. It is characterized by a low-renin plasma activity,
salt sensitivity and a high rate of end-organ damage52. To our
knowledge, the closest mouse model to low-renin hypertension
may be the Npra (Atrial Natriuretic Protein Receptor A) knockout
mice characterized by increased BP and low plasma renin activity,
but no salt sensitivity53. On the other hand, Nppa (which encodes
ANP) knockout mice exhibit salt sensitivity, but they are not
hypertensive under a regular salt diet54. Of note, the Nppa system
is not altered in Gata5-null mice. Both Nppa and Nppb transcripts
level are unchanged in embryonic Gata5-null hearts, but are
increased in adult hypertrophied hearts9. Npra transcript levels are
also unchanged in Gata5-null kidneys. The Gata5-null mice
exhibit several essential features of low-renin hypertension:
significant increase in BP, low-renin plasma activity, salt
sensitivity and severe renal alterations. Similar to patients with
low-renin hypertension, Gata5-null mice respond well to thiazide
therapy and may be a useful model to further analyse the
pathophysiology and progression of disease.
Although the results from the three consortia CHARGE,
GLOBAL BPgen and AGEN-BP represented an important advance
in hypertension research, the collective effect of all BP loci
identified explains only a small fraction (2%) of BP heritabil-
ity5,55,56. Additional variants, associated with BP traits remain,
therefore, to be identified. Here, we report two common GATA5
variants that are associated with prescription of anti-hypertensive
medication in two independent populations from the
ADVANCE23 and OHGS24 studies, suggesting that GATA5
might also be involved in BP regulation in humans. Although
the variants identified would not affect GATA5 protein sequence
(rs6061245 is located within the third intron of GATA5, whereas
rs6587239 is a synonymous polymorphism in the fifth exon), they
might have consequences on GATA5 expression levels. Indeed,
with better insight into the factors regulating protein expression,
intronic and synonymous single-nucleotide polymorphisms
(SNPs) have received increased attention. The functional role of
SNPs within introns in altering transcription levels has been
clearly validated and linked to several pathologies including
hypertension57,58. Similarly, synonymous SNPs are linked to a
plethora of diseases in humans59. While the mechanisms involved
are not fully elucidated, experimental and computational studies
indicate that synonymous SNPs could impact splicing accuracy,
translation fidelity, mRNA structure and protein expression/
folding by modifying mRNA stability and translational processes59.
In conclusion, we have identified Gata5 as a new gene involved
in the regulation of BP. Gata5-null mice represent a unique
model of hypertension that reproduces several features of human
essential hypertension. This model might be especially useful for
addressing the pathophysiology of age-related salt sensitivity in
hypertension, and for elucidating the mechanisms of low-renin
hypertension. Finally, the Gata5-null mice provide a new tool for
addressing gene–gene and gene–environment interactions in the
onset and progression of hypertension and other diseases of the
endothelium.
Methods
Animals. All the experiments carried on mice were approved by the institutional
animal care and use committee (IACUC) of the University of Ottawa under the
reference: BMI-1983. Floxed Gata5 mice9 were used and gene inactivation was
achieved by crossing with mice harbouring the CRE recombinase under the control
of the cytomegalovirus (CMV) promoter (for obtaining Gata5-null mice) or the
Tie2 or SM22 promoters (for endothelium- or smooth-muscle-specific inactivation,
respectively). Both Tie2 and SM22-cre mice are on a C57/B6 background. SM22-
Cre mice were obtained from the Jackson Laboratories (stock number 01791).
Non-null littermates were used as controls.
BP measurement. Systolic and diastolic BPs as well as heart pulse were measured
by tail-cuff plethysmography in trained conscious mice (3-month-old male and
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female mice for steady-state experiment on Gata5-null mice, and Tie2 and SM22-
cre Gata5-null mice) using a BP2000 Visitech model. BP was measured every day
in the same room at the same hour for 8 consecutive days. The BP measurements
presented are the mean of the last 5 consecutive days.
Echocardiography. Transthoracic echocardiography (Doppler and M-mode) was
performed using a visual sonics Vevo 770 ultrasound system with a RMV 707
30-MHz transducer (4-month-old male mice).
High- and low-salt diet. Acute salt loading: 1% NaCl diluted in drinking water
was administered ad libitum to mice (3-month-old male mice) for 24 h and urine
was collected by metabolic cages.
Chronic high- and low-salt study was performed on 8-month-old male mice:
high- (8% NaCl, TD. 92012) and low-salt (0.025% NaCl, TD. 90228) diets were
purchased from Harlan Laboratories. BP was measured the week before treatment.
High-salt diet was administered for 6 weeks. BP was measured the last week of the
high-salt diet. Low-salt diet was administered for 10 days and BP was measured the
last week on this diet. At the end of treatment, mice were fed with regular food diet
(0.5% NaCl) for 4 weeks, with BP being measured the last week on this diet.
Hydrochlorothiazide administration. HCTZ was purchased from Sigma-Aldrich
(H2910). Two doses were administered to 3-month-old male mice: (1) a low dose,
HCTZ was administered in drinking water (700mg l 1) resulting in a dose of
2.8mg per day, and (2) a high dose, HCTZ was administered in drinking water
(700mg l 1) and chow (1.25mg g 1), resulting in a dose of 8mg per day. Each
treatment was administered for 5 days. BP was measured a week before treatment
and during all duration of HCTZ administration.
Hydralazine administration. Hydralazine hydrochloride (Hydra) was purchased
from Sigma-Aldrich (H1753). Hydra was diluted in drinking water at the dose of
200mg l 1 and administered for 4 weeks to 3-month-old male mice. Hydra was
renewed every 72 h. BP was measured the week before treatment and the last week
of treatment.
Plasma electrolyte measurement and plasma renin activity. Blood was col-
lected from the facial vein (3- and 12-month-old male mice) in heparinized tubes
and plasma was isolated by centrifugation (1,000g, 15min). Plasma was stored at
 80 C. Idexx Laboratories (Markham, ON, CA) measured plasma electrolytes
concentrations. Plasma renin activity was measured using the fluorometric Renin
assay kit from Abcam (Ab138875) using a TF3/TQ3 FRET peptide. Briefly, the
fluorescence of TF3 is quenched by TQ3. Upon cleavage into two separate frag-
ments by renin, the fluorescence of TF3 is recovered. The fluorescent signal was
measured using a BMG Fluostar Galaxy fluorescence microplate reader at Ex/
Em¼ 540/590 nm.
Urinary electrolyte and aldosterone measurement. Three- and 12-month-old
male mice were kept in metabolic cages for 5 consecutive days. Urine was collected
every 24 h for the last 3 days. Idexx Laboratories measured plasma electrolytes
concentrations. Aldosterone was measured using the Cayman Enzyme immu-
noassay (10004377).
Tubules and glomeruli isolation. Individual freehand microdissected proximal
tubules, thick ascending limb and cortical collecting ducts were isolated from
control mice following a protocol described in ref. 60. Briefly, 3-month-old C57Bl/6
male mice weighing 22–25 g were killed by intraperitoneal injection of ketamine
(100mg kg 1) and xylazine (10mg kg 1) for anaesthesia followed by decapita-
tion. The left kidney was quickly removed, and 2–3-mm coronal slices were placed
in chilled dissection dishes 8 C for freehand dissection. The composition of
standard dissection medium was as follows: NaCl: 105mM; NaHCO3: 25mM; Na
acetate: 10mM; NaHPO4: 2.3mM; KCl: 5mM; CaCl2: 1.8mM; MgSO4: 1.0mM;
glucose: 8.3mM; alanine: 5mM and 1% albumin. The final osmolality was set at
300mOsmol kg 1. Glomeruli were isolated using magnetic microbeads61. Briefly,
3-month-old male mice were anesthetized by intraperitoneal injection of ketamine
(100mg kg 1) and xylazine (10mg kg 1) and perfused with 8 107 Dynabeads
M-450Tosylactivated (Invitrogen, ref 140.13) diluted in 40ml of phosphate-
buffered saline through the heart. The kidneys were removed, minced into 1-mm3
pieces and digested in collagenase (1mgml collagenase A—Roche, ref
10103578001- and 100Uml 1 DNAse I—Roche, ref 10104159001—in Hank’s
balanced salt solution—HBSS) at 37 C for 30min with gentle agitation. The
collagenase-digested tissue was gently pressed through a 100-mm-cell strainer using
a flattened pestle and the cell strainer was then washed with 5ml of HBSS. The
filtered cells were passed through a new cell strainer without pressing and the cell
strainer washed with 5ml of HBSS. The cell suspension was then centrifuged at
200g for 5min. The supernatant was discarded and the cell pellet was resuspended
in 2ml of HBSS. Finally, glomeruli containing Dynabeads were gathered by a
magnetic particle concentrator and washed for at least three times with HBSS.
During the procedure, kidney tissues were kept at 4 C except for the collagenase
digestion at 37 C.
In vitro vascular reactivity of isolated arteries. Mesenteric vascular beds were
isolated from Gata5-null mice and their controls (3-month-old male mice) and
placed into a container filled with ice-cold Krebs–Henseleit modified physiological
salt solution (in mmol l 1: 120 NaCl, 25 NaHCO3, 4.7 KCl, 1.18 KH2PO4, 1.18
MgSO4, 2.5 CaCl2, 0.026 EDTA and 5.5 glucose). Second-order branches of
superior mesenteric artery were dissected and cut into rings of 2mm in length and
were mounted on a multichannel wire myograph (Model 620M, DMT, Danish
Myo Technology, Denmark). Vessel segments were mounted on 25-mm wires in a
vessel bath chamber for isometric tension recording. Each chamber contained 5ml
of physiological salt solution bubbled constantly with 95% O2 plus 5% CO2, 37 C.
At the beginning of each experiment, arteries were contracted by administration of
60mmol l 1 high-Kþ solution or 10 mmol l 1 phenylephrine to test for functional
integrity. Endothelium-dependent and  independent relaxations were assessed by
measuring isometric force responses to acetylcholine (1 nmol l 1 to 10mmol l 1)
and Diethylamine NONOate sodium salt hydrate (1 nmol l 1 to 10 mmol l 1).
Contractile responses mediated by phenylephrine (1 nmol l 1 to 10 mmol l 1)
were also evaluated in the arteries.
Tissue sampling. Hearts, kidneys and mesenteric arteries were harvested from
3–4- and 12-month-old male mice and rinsed in ice-cold PBS. The heart was
weighed and cut into two parts (transversal cut). The base was fixed in 4%
paraformaldehyde for morphological studies. The apex was kept for mRNA and
protein studies. Kidneys were weighted. One kidney was cut transversally into two
parts, one for mRNA, and the other for proteins extraction. The second kidney was
cut transversally into two parts, one was fixed in 4% formaldehyde and the other
was included in tissue-tek and frozen in liquid nitrogen-cooled isopentane for
immunofluorescence studies. All non-fixed samples were frozen in liquid nitrogen,
and kept at  80 C.
Flow cytometry. Immune cells of 3-month-old male mice were isolated from
spleen, kidney, bone marrow and thymus by flushing and pelleting (bone marrow)
or by mechanical dissociation followed by centrifugation through a percoll gradient
(kidney, spleen and thymus). Erythrocytes were lysed with ammonium-chloride-
potassium lysing buffer, and the resulting leukocytes were counted on a haemo-
cytometer. Cells were stained for flow cytometry analysis with anti-CD45 (Becton
Dickinson, ref: 25-0451-82, dilution: 1/1,000), anti-B220 (eBioscience, ref: 45-0452-
80, dilution: 1/1,000), anti-CD11b (eBioscience, ref: 12-0112-82, dilution: 1/1,000),
anti-CD11c (eBioscience, ref: 11-0114-85, dilution: 1/1,000), anti-NKp46
(eBioscience, ref: 48-3351-82, dilution: 1/1,000), anti-CD8 (eBioscience,
ref: 17-0081-81, dilution: 1/1,000), anti-TCRb (Becton Dickinson, ref: 563221,
dilution: 1/1,000) and Fixable Viability Dye (eBioscience, ref: 65-0865-14). Samples
were acquired on CyAnADP 9 flow cytometer (Beckman Coulter) using Summit
acquisition software (V). Data were analysed using Kaluza flow analysis software V
(Beckman Coulter). An example of this analysis is shown in Supplementary Fig. 12.
Histology. Tissues (Kidney and hearts) fixed in 4% paraformaldehyde were
embedded in paraffin, sectioned at 4-mm intervals, and processed by the uOttawa
Histology Core facility. Similarly, all stainings (Periodic acid Schiff, Masson’s tri-
chrome staining) were performed by the histology core of the University of Ottawa.
Masson’s trichrome was used to evaluate fibrosis. Fibrosis area was determined
using imageJ (1.43) software.
Immunofluorescence. Transverse kidney 4-mm sections were stained using primary
antibodies against CD45 (Pharmigen, 550539, dilution: 1/500), F4/80 (Abcam
Ab6640, dilution: 1/500) or NCC (Millipore, AB3553, dilution: 1/1,000). Briefly,
sections were blocked with 5% BSA for 30min and incubated with the primary
antibody overnight at room temperature. After rinsing with PBS, the sections were
incubated for 1 h with the appropriate secondary antibody (Donkey anti-rat IGG
(Hþ L) secondary antibody, Alexa Fluor 594 conjugate—Life technologies, ref
A-21209, dilution: 1/250—for CD45 and F4/80, and Goat anti-rabbit IGG (Hþ L)
secondary antibody, Alexa Fluor 488 conjugate—Life technologies, ref A-11008,
dilution: 1/250- for NCC). Images were acquired blindly to the genotype or treat-
ments with a Zeiss AxioObserver.D1 Microscope mounted with an AxioCam MRm
CCD. A minimum of five fields per section of renal cortex was recorded at  10 and
 20. The positive-stained area was determined using imageJ (1.43) software.
Scoring of kidney damage. The pathologist of the Kidney Research Center
(Ottawa Hospital) acquired images of kidney sections at  40 with a Zeiss
AxioObserver A1microscope mounted with an Olympus DP73 digital colour
camera and analysed them (blind to the genotype or treatment of mice). A semi-
quantitative score was used to evaluate the degree of damage62. A minimum of 50
glomeruli in each group was examined and the severity of the lesion was graded
from 0 to þ 3: a þ 1 lesion represented an involvement of 25% of the glomerulus,
þ 2 of 25–50%, while a þ 3 lesion indicated that 50–75% of the glomerulus was
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involved. Observation for other pathological lesions included glomerular collapse
(as absent, partial or total); glomerular hypertrophy (absent or present);
distribution of glomerulosclerosis (absent, diffuse widespread in the cortex,
superficial focal, located in the inner or outer half of the cortex and focal juxta-
medullar.
Human primary endothelial cells. Human primary endothelial cells were pur-
chased from Promocell: Human Coronary artery endothelial cells (ref C-14022,
Lot: 91001010.7P); Human Cardiac Microvascular Endothelial Cells (ref C-14029,
Lot: 20224401P); Human Pulmonary Microvascular Endothelial Cells (ref C-14027,
Lot: 9090301P) and HDMECs (ref C-14016, Lot: 4060603P).
Generation of GATA5 knockdown HDMEC cell line. GATA5 MISSION TRC2
pLKO.shRNA (TRCN0000431556) and MISSION TRC2 pLKO-puro Non-Mam-
malian shRNA Control (SHC202) plasmids were purchased from Sigma-Aldrich.
Viral particles were generated by co-transfection of phoenix cells with the lentiviral
vector (GATA5 TRC2 shRNA or the shRNA control plasmids), the packaging
vector psPAX2 and the envelope vector pMD2G. Co-transfection was performed
using the Qiagen’s Effectene transfection reagent (301425). Twenty-four hours
after transfection, medium was discarded and replaced by Endothelial Growth
Medium 2 (Promocell, C-22021). After 48 h, the medium (EGM2) was collected,
filtered and used for infection of HDMECs (Promocell, C-14016). Infected cells
were selected with addition of puromycin (Sigma-Aldrich, P8833) to culture
medium at the concentration of 2.5 mgml 1 for 15 days. Control (HDMEC-
pLKO-Ctrl) and HDMEC-GATA5-KD cells were then grown and maintained in
EGM2 containing puromycin at the concentration of 0.25 mgml 1.
Microarray analysis. mRNA from HDMEC-GATA5-KD cells and their controls
(HDMEC-pLKO-Ctrl) was extracted using Qiagen’s RNEASY mini-kit (74104)
following the manufacturer recommendations. mRNA quality and integrity were
assessed with Fragment analyser (Advanced Analytical), and samples with
RQN49 were retained for analysis (three of each group). StemCore Laboratories at
Ottawa Institute Research Hospital performed samples preparation and hybridi-
zation on Affymetrix Human Gene 2.0 ST arrays (902136). Non-used mRNA was
used for qPCR. Fold-change analysis was performed using the R package limma, P
values were Benjamini-Hochberg (BH) adjusted. HuGene chip annotations are
based on the HuGene-2_0-st-v1.na35.hg19.transcript.csv annotations downloaded
from Affymetrix. The first gene identifier associated with a given probe set
(transcript cluster identifier) was chosen as the symbol representing it. The path-
way functional analysis was performed through the use of Qiagen’s Ingenuity
Pathway Analysis (IPA, Qiagen, Redwood City, www.qiagen.com/ingenuity).
Microarray data have been deposited in the Gene Expression Omnibus database
(NCBI) under accession code: GSE71838.
QPCR. Frozen tissues (kidneys, heart and mesenteric arteries) were homogenized
in TRIzol (Life Technologies, 15596018) using FastPrep beads (MP-Bio, 6913-100).
Due to the small amount of mRNA expected from mesenteric arteries, once
separated in the aqueous phase, mRNA was then extracted using RNeasy micro-kit
(Qiagen, 74004). cDNAs were generated using the Omniscript RT kit (Qiagen,
205113), and qPCR was performed as previously described. Briefly, transcript levels
were analysed in a RotorGene 6000 apparatus (Corbett Life Science). The reactions
were performed in duplicate for each sample using the RotorGene SYBR Green
PCR Kit (Qiagen, 204076). To normalize gene expression, we used the geometric
mean of multiple internal reference genes Ct (RS16, Ubc, Hprt and Gapdh for mice
experiments, GAPDH and UBC for human cell experiments) as described by
Vandesompele et al.63 Values in control conditions were set as 1 for each gene. The
sequences of the specific primers are detailed in Supplementary Table 3.
Western blot. Endothelial cells (HDMEC-GATA5-KD and HDMEC-pLCKO-
Ctrl), mesenteric arteries and kidney proteins were extracted in SDS 1% buffer
containing PhosSTOP phosphatases inhibitor (Roche, 04906845001) and cOmplete
protease inhibitor (Roche, 04693116001) reagents. Protein concentration was
estimated according to the Pierce method. Membranes were incubated overnight
(4 C) with the respective antibodies: GATA5 (Santa Cruz, Sc-47600, dilution:
1/1,000), phospho-NOS3-ser1177 (Cell Signalling, ref 9571, dilution: 1/2,000),
phospho-NOS3-thr495 (Cell Signalling, ref 9574, dilution: 1/500), NOS3 (Abcam,
ref Ab66127, dilution: 1/1,000), phospho-Akt-ser473 (Cell Signalling, ref 9271,
dilution: 1/1,000), phospho-Akt-thr308 (Cell Signalling, ref 4056, dilution:
1/1,000), Akt (Cell Signalling, ref 9272, dilution: 1/1,000), phospho-PTEN-ser380
(Cell Signalling, ref 9551, dilution: 1/2,500), PTEN (Cell Signalling, ref 9188,
dilution: 1/1,000), phospho-PKD1-ser241 (Cell Signalling, ref 3061, dilution:
1/2,500), PKD1 (Cell Signalling, ref 3062, dilution: 1/1,000), phospho-(Ser/Thr)
PKA substrate antibody (Cell Signalling, ref 9621, dilution: 1/1,000), NCC
(Millipore, AB3553), aENaC (Pierce, PA1–920A, dilution: 1/1,000), NKCC2
(Abcam, Ab171747, dilution: 1/1,000), a1-Na/K ATPase subunit (Abcam, Ab7671,
dilution: 1/10,000) and b1-Na/K ATPase subunit (SantaCruz Biotechnologies,
Sc-25709, dilution: 1/1,000). Human GATA5 was detected with an antibody
generated by the laboratory (dilution: 1/1,000)9. Chemiluminescent signal was
produced using ECLþ solution and detected with a LAS-4000 luminescent image
analyzer (General Electric). Relative densitometry was determined using the
computer software ImageQuant TL (General Electric). Actin (Santa Cruz
Biotechnology, ref Sc-1616) was used as a protein-loading control. Full scans of
western blots are available in Supplementary Fig. 9.
Nitrotyrosine measurement. Mesenteric arteries proteins were extracted in SDS
0.25% buffer containing PhosSTOP phosphatases inhibitor (Roche, 04906845001)
and cOmplete protease inhibitor (Roche, 04693116001) reagents. Protein con-
centration was estimated according to the Pierce method. Nitrotyrosine content
was measured with the 3-Nitrotyrosine ELISA Kit (ab116691) from Abcam
according to the manufacturer’s recommandations. Colour development was
measured at 600 nm with a powerwave XS2 microplaque spectrophotometer
(Biotek, Winooski, USA).
Human association studies. OHGS (cohort 1) is a case–control study aimed at
discovering genetic variants that modify the risk of CAD, independent of diabetes.
Study participants were recruited from the angiography clinic of the University of
Ottawa Heart Institute or from the Ottawa Community for Asymptomatic Con-
trols. CAD cases were defined as having at least one coronary artery with 450%
stenosis and controls were asymptomatic of CAD or among angiographic samples,
had minimal (o30%) coronary artery stenosis. Diabetics were excluded from
participating in the study. More detailed information on the CAD definitions and
recruitment procedures of the OHGS have been detailed previously. Supplementary
Table 4 details the clinical characteristics of patients taking or not hypertensive
medication23,64. The OHGS samples were genotyped on Affymetrix 500 K or 6.0
GWAS SNP genotyping arrays. Genotyped variants 56 kb either side of the GATA5
gene (within the genomic coordinates of chr20:60,982,420–61,107,159) were tested
for their association with hypertensive medication use.
The ADVANCE (cohort 2) trial is a factorial, multi-center, randomized
controlled clinical of 11,140 participants recruited from 215 centres in 20 countries
assessing the effect of treatment with hypertension and glucose-lowering drugs on
incident diabetic complications5,24. All subjects were type-2 diabetic patients, and
inclusion criteria into ADVANCE were the following: age of 55 years and older and
diagnosis of type-2 diabetes at age of 30 years or older and one of the following: (1)
a history of major macrovascular disease, or (2) history of major microvascular
disease, or (3) diagnosis of type-2 diabetes over 10 years before entry in study, or
(4) presence of another major risk factor for vascular disease (including smoking,
dyslipidemia or microalbuminuria), or (5) age of 65 years or older. All subjects
were ascertained at entry into the study for a variety of macro- and microvascular
diabetes associated phenotypes including hypertension, defined as being treated for
hypertension; coronary heart disease symptoms, including myocardial Infarction,
stroke, transient ischaemic attack, angina and major adverse coronary events; and
for chronic kidney disease, associated phenotypes including glomerular filtration
rate and urinary albumin creatinine ratio. A subset of 2301 ADVANCE subjects
was genotyped using the Affymetrix Genome-Wide Human SNP Arrays 5.0 or 6
and passed quality controls. They were used for further association analysis.
Supplementary Table 5 details the clinical characteristics of those taking or not
hypertension medications in the ADVANCE GWAS study.
In silico analysis. Human Splicing Finder is an online tool to predict the effects of
mutations on splicing signals or to identify splicing motifs in any human
sequence25. It contains all available matrices for auxiliary sequence prediction.
Consequences of GATA5 variant rs6587239 on SRSs were analysed by comparative
analysis of motifs present on GATA5 fifth exon with either an adenine or a guanine
(ancestral) on position 27.
Statistics. The results are reported as mean±s.e.m. Statistical analysis was per-
formed using Graphpad V5 software. The in vivo experiments were performed
blind to the genotype and, when possible, to the experimental conditions. The data
were analysed blind to the genotype and the experimental conditions. Sample size
was determined empirically based on pilot analyses. All inclusion and exclusion
criteria were pre-established according to the IACUC guidelines. The Kolmogorov–
Smirnov (when 5rno7) or the d’ Agostino–Pearson test (when nZ7 per group)
was used to analyse normality. Two-group comparisons were performed using one
tailed t-test if normality was confirmed; otherwise the Mann–Whitney test was
used. The Mann–Whitney test was also used for statistical analysis of experiment
with no5 per group. ANOVA was used for multivariate comparisons followed by
Bonferonni correction for multiple comparisons. HCTZ and salt-sensitivity
experiments were analysed by a repeated measures two-factor ANOVA test fol-
lowed by Bonferonni correction for multiple comparisons. Vascular reactivity dose
responses were analysed by comparison of best-fit values (effector concentration
for half-maximum response and Hill slope) using an F-test. For GWAS studies,
Frequentist association tests for additive model were performed using SNPTEST49
(version 2.5). SNPTEST implements logistic regression analysis for discrete
variables and linear regression analysis for continuous variables. R (version 3.1.2)
was used for data handling, and SAS Enterprise Guide (version 4.3) was used to
create the clinical characteristics tables. Differences with Po0.05 are considered
significant.
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